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S308 Poster Session Iof using donors that are not fully matched on both GVHD incidence
and overall survival. Historically there is evidence that an isolated C
mismatch may not affect these outcomes but this has been evaluated
almost exclusively in adult patients with hematologic malignancies.
We collected data on a 146 consecutive pediatric patients (median
age 9 years) who received an unrelated donor transplant at Children’s
Hospital Boston from 1/2004 through 12/2010 for malignant and
nonmalignant conditions. 97% received bone marrow as the stem
cell source and 97% received fully myeloablative conditioning.
75% underwent HSCT for a hematologic malignancy (leukemia/
lymphoma), 11% for immunodeficiency and the remainder for other
indications, primarily bone marrow failure syndromes. 70% of pa-
tients had a donor fully matched at both A,B,C,DR, DQ loci on
high resolution typing, 10% had a single C mismatch and the re-
maining 20% had a donor with 1 or 2 other mismatches excluding
a single C mismatch (none had a DR mismatch and all were at least
a 5/6 match on A, B, DR). 45% experienced GVHD: 13% acute
only, 51% chronic only and 32%both. There was no statistically sig-
nificant difference in the proportion of patients who had acute
GVHD of any grade and/or limited or extensive chronic GVHD be-
tween those having a fully matched, single C mismatch or other mis-
matched donor (p5 0.7). There was also no significant difference in
survival between the groups. 100 day and 1 year overall survival were
93%/77% with fully matched donors, 87%/60% for single C mis-
matched donors (p 5 0.2) and 96%/76% for other mismatched do-
nors. Thus it appears that in the era of high-resolution HLA typing
and improved supportive care HLA mismatched donors can provide
outcomes similar to those using fully matched donors in pediatric
patients undergoing HSCT for malignant and nonmalignant
conditions.Table 1. Association between AUC-all and AUC generated
by LSSs
Sample times
(hours after start of
infusion) Adjusted r2
Mean bias
(%; range) Precision (%)
2, 3 and 4 0.9962 0.05 (-5.3 to 4.6) 3.6
2, 3, 4 and 10 0.9981 0.03 (-2.0 to 2.0) 1.2
2, 2.5, 3, 4 and 10 0.9990 0.05 (-2.0 to 3.0) 0.9278
EPIDEMIOLOGY OF BACTERIAL, FUNGAL AND VIRAL INFECTIONS IN
CHILDREN AND ADOLESCENTS AFTER HEMATOPOIETIC STEM CELL
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The epidemiology of bacterial, fungal and viral infections was
retrospectively analyzed in a cohort of 759 children and adolescents
who underwent allogeneic hematopoietic stem cell transplantation
(HSCT) in a single institution, between 1990-2009, to study the
impact of changes in transplantation methodology on the distribu-
tion of pathogens and mortality due to infections. There were 243
matched-related, 239 matched-unrelated (MUD) and 176 haplo-
identical donor transplants. Independent logistic regression was
conducted at 0-30 days (A), 30-100 days (B) and .100 days (C)
post-transplant. On multivariate analysis, total body irradiation (p
5 0.001, A; 0.005, C), apheresis product (p 5 0.02, A; 0.01, B),
acute (p 5 0.002, B) and chronic (p 5 0.03, C) graft vs host disease
(GVHD) were associated with higher risk for bacterial infections at
the respective time periods. CMV serostatus (p 5 0.05, B), pres-
ence of acute (p 5 0.001, B), chronic GVHD (p\0.001, C) and
age .10 yrs (p 5 0.02, C) were associated with higher risk for fun-
gal infections. CMV serostatus (p 5 0.0005, A; 0.03 B; 0.002 C),
acute (p 5 0.01, A) and chronic GVHD (p 5 0.001, C), were asso-
ciated with higher risk for viral infections. MUD donor transplants
were associated with a higher risk of viral infections (p 5 0.001).
Bacterial (p 5 0.002) and fungal (p 5 0.0004) infections in period
A, decreased in the 2005-2009 era. There were 321 episodes of bac-
teremia in 231(30%) patients, of whom 168 episodes (52%) were in
period C. Staphylococcus epidermidis (33%) and Escherichia coli (12%)
were the most common causes of bacteremia. Candidemia, mostly
C.albicans, was detected in 49 (6%) patients, 26 (54%) in period C.
There were 45 patients with proven aspergillosis, 20 (44%) in pe-
riod A. Non-aspergillus molds were detected in 16 (2%) patients.
CMV and adenoviremia was detected in 146 (20%) and 68 (9%)
patients respectively. Parainfluenza was the most common respira-
tory viral infection detected in 70 (9%) patients, 35(50%) in period
C. This is the largest retrospective study providing a time line of
infections in children and adolescents who have undergone alloge-
neic HSCT.279
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Haematopoietic stem cell transplantation (HSCT) outcomes may
be optimized by cyclosporine dose adjustment according to systemic
exposure (measured by area under the curve (AUC)) rather than
trough concentration. We have previously developed and validated
a limited sampling strategy (LSS) for estimating cyclosporine AUC
after the initial IV dose in children undergoing HSCT. In this study
we aim to develop a LSS to estimate AUC at steady-state.
Children undergoing myeloablative HSCT and given cyclospor-
ine q12h as a 2-hour infusion and methotrexate/methylprednisolone
for acute graft-versus-host disease (GVHD) prophylaxis were eligi-
ble. Cyclosporine AUC was determined once weekly until engraft-
ment using 9 concentration-time points. Steady state was defined
as being reached after administration of 4 identical doses.
The association between cyclosporine AUC using all available
data points (AUC-all) and the AUC values predicted by each LSS
was described using the adjusted coefficient of determination (r2);
values . 0.9 were acceptable. Precision and mean bias \ 15%
were acceptable.
18 children (0.3-17 years) participated. Mean actual dose infu-
sion time was 1236 4.4 min. Mean AUC-all at steady state was
489461386 h*mcg/L. Individual cyclosporine whole blood concen-
trations drawn at 2, 2.5, 3, and 4 hours after the start of the infusion
correlated most highly with AUC-all (Spearman rho coefficient:
0.847, 0.926, 0.942, and 0.903, p\0.0001, respectively). Values of
AUC predicted by the 3, 4 and 5-point LSS were strongly associ-
ated with AUC-all (spearman rho coefficient . 0.998;
p\0.0001).The 3-point LSS (2, 3 and 4 hours) is likely the method
of choice for determining cyclosporine AUC at steady state when
given as 2 hour infusion to children undergoing HSCT. Validation
of the LSS in a different sample is required before this LSS strategy
can be implemented. The relationship between acute GVHD and
cyclosporine AUC at different time periods after HSCT merits
further study.280
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Matched sibling donor hematopoietic cell transplantation (HCT)
is considered the standard of care for many disorders, yet the donor’s
emotional and physical needs may be overlooked and the donor
viewed as a therapeutic modality in the process of saving the life of
an ill sibling. In this IRB-approved study, we explored the meaning
of the donor’s experiences through his own words and recollections,
and the contextual influences and critical events across the transplant
trajectory. A semi-structured interview was conducted in private
